Anastasia Ustyugova

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes

William T. Abraham, JoAnn Lindenfeld, Piotr Ponikowski et al. · European Heart Journal · 2020 · 212 citations

Medicine, Cardiology, Pharmacotherapy +16

Health Care Costs by Type of Expenditure across eGFR Stages among Patients with and without Diabetes, Cardiovascular Disease, and Heart Failure

Gregory A. Nichols, Anastasia Ustyugova, Anouk Déruaz‐Luyet et al. · Journal of the American Society of Nephrology · 2020 · 70 citations · Full text

Public Affairs, Nephrology, Electronic Health Records +16

Rationale and Design of The Emperial-Preserved and Emperial-Reduced Trials of Empagliflozin in Patients with Chronic Heart Failure

William T. Abraham, Piotr Ponikowski, Martina Brueckmann et al. · European Journal of Heart Failure · 2019 · 59 citations · Full text

Pharmacy, Cardiology, Pharmacotherapy +17

Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial

Odette S. Reifsnider, Christoph Wanner, Egon Pfarr et al. · American Journal of Kidney Diseases · 2021 · 50 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study

Jakob S. Knudsen, Lisbeth M. Baggesen, Maria Lajer et al. · PLoS ONE · 2020 · 37 citations · Full text

Medicine, Cardiology, Pharmacology +12